| Literature DB >> 29382107 |
David Weetman1, Basile Kamgang2, Athanase Badolo3, Catherine L Moyes4, Freya M Shearer5, Mamadou Coulibaly6, João Pinto7, Louis Lambrechts8,9, Philip J McCall10.
Abstract
The Zika crisis drew attention to the long-overlooked problem of arboviruses transmitted by Aedes mosquitoes in Africa. Yellow fever, dengue, chikungunya and Zika are poorly controlled in Africa and often go unrecognized. However, to combat these diseases, both in Africa and worldwide, it is crucial that this situation changes. Here, we review available data on the distribution of each disease in Africa, their Aedes vectors, transmission potential, and challenges and opportunities for Aedes control. Data on disease and vector ranges are sparse, and consequently maps of risk are uncertain. Issues such as genetic and ecological diversity, and opportunities for integration with malaria control, are primarily African; others such as ever-increasing urbanization, insecticide resistance and lack of evidence for most control-interventions reflect problems throughout the tropics. We identify key knowledge gaps and future research areas, and in particular, highlight the need to improve knowledge of the distributions of disease and major vectors, insecticide resistance, and to develop specific plans and capacity for arboviral disease surveillance, prevention and outbreak responses.Entities:
Keywords: Aedes aegypti; Aedes albopictus; Aedes formosus; Zika; chikungunya; dengue; vector; yellow fever
Mesh:
Year: 2018 PMID: 29382107 PMCID: PMC5858289 DOI: 10.3390/ijerph15020220
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Estimated population at risk of infection (PAR) by each arbovirus and by overlapping arboviruses in Africa, 2015. Population estimates were calculated using the methods and data sources as defined and cited in Figure 1a,b, respectively.
| Infection | Estimated Population at Risk | Percentage of African Population |
|---|---|---|
| Chikungunya | 271 million | 23% |
| Dengue | 750 million | 63% |
| Yellow fever * | 21 million | 2% |
| Zika | 406 million | 34% |
| At least one of the above | 831 million | 70% |
* The value for yellow fever has been adjusted to account for reductions in the population at risk following vaccination programmes.
Figure 1The distributions of chikungunya, dengue, yellow fever and Zika virus infections in humans in Africa. (a) Areas at risk of one, two, three or all four infections; map generated as described in Supplementary Methods. (b) Locations of reported infections (symptomatic and non-symptomatic) of dengue, chikungunya, Zika and yellow fever [24,25,26,27,28].
Figure 2Reports of mosquito occurrence and areas of predicted environmental suitability for Aedes albopictus and Ae. aegypti in Africa [36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64]: (a) Ae. aegypti; (b) Ae. albopictus.
Records of insecticide resistance in Aedes species (1990 onwards) from African mainland countries and islands. Resistance is classified according to WHO standards as resistant (R) < 90% mortality, suspected resistance (RS) 90–97% mortality, or susceptible (S) > 97% mortality in adult (a) tube or larval (l) bioassays. Brief details of resistance mechanisms are shown where reported. Studies are ordered by species, then from North-West toward South-East. Blank cells indicate that the phenotype or mechanism was not investigated.
| Study | Year | Country | Area | Species | DDT (a) | Pyr I (a) | Pyr II (a) | Carb (a) | OP (a) | Temephos (l) | Other (l) | Metabolic Resistance | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [ | 2013 | Madeira | Funchal, Paul do Mar | R | R | R | R, S | F1534C; V1016I | MFO, esterases (biochemistry); PBO, DEM significant (synergist; metabolizing genes overexpressed) | |||||
| [ | 2009 | Cape Verde | Santiago | R | S | S | R | S | ||||||
| [ | 2012 | Cape Verde | Santiago, Praia | R | S | S | Not detected | MFO, esterases, GSTs (biochemistry) | ||||||
| [ | 2009 | Senegal | Dakar | R | S | R, RS | R | S | ||||||
| [ | 2010 | Côte d’Ivoire | Abidjan | S | RS, S | R, RS | ||||||||
| [ | 2014 | Côte d’Ivoire | Abidjan | R | S | RS | RS | S (DDT, Pyr) | ||||||
| [ | 2012–2013 | Ghana | Accra | R | R | R | ||||||||
| [ | 2013–2014 | Ghana | Widespread | R | R, RS, S | F1534C; V1016I | ||||||||
| [ | 2013–2014 | Ghana | Widespread | R | R, RS, S | F1534C | ||||||||
| [ | 2011–2012 | Nigeria | Lagos | R | S | RS, S | ||||||||
| [ | 2013 | Nigeria | Kwara State | S | S | R | ||||||||
| [ | 2007 | Cameroon | Widespread | RS | S | S | S | S | S | |||||
| [ | 2015–2016 | Cameroon | Yaoundé | R | S | R | R, S | S | Not detected | Limited effect of synergist PBO | ||||
| [ | 2013 | Central African Rep. | Bangui | R, RS | RS, S | S | S | S | S | Not detected | MFO, esterases, GSTs (biochemistry) | |||
| [ | 2007 | Gabon | Libreville | R | S | S | S | S | S | |||||
| [ | 2009, 2010 | Sudan | Port Sudan | R | RS, S | S | R, RS | |||||||
| [ | 2015 | Tanzania | Dar es Salaam | R, RS | R, RS | |||||||||
| [ | 2010–2011 | Mayotte | Petit Terre | S | S | S | S (multiple) | |||||||
| [ | 2007 | Cameroon | Widespread | R | RS, S | S | S | S | S | |||||
| [ | 2015–2016 | Cameroon | Yaounde | R | R, S | R, RS | R, RS | S | Not detected | Variable effect of synergist PBO among locales | ||||
| [ | 2014 | CAR | Bangui | R, RS, S | R, RS, S | RS, S | RS, S | S | S | Not detected | MFO, esterases, GSTs (biochemistry) | |||
| [ | 2007 | Gabon | Libreville | S | ||||||||||
| [ | 2010–2011 | Mayotte | Kaweni | S | S | S | S (multiple) |
Abbreviations: DDT (dichlorodiphenyltrichloroethane); Pyr (pyrethroid); Carb (carbamate); OP (organophosphates); MFO (mixed function oxidases); PBO (piperonyl butoxide); DEM (diethyl maleate); GST (glutathione S-transferase).